Cardiometabolic Disorders News

Black adolescents who face more racial discrimination may be more likely to have metabolic syndrome at age 31 years, according to findings published in JAMA Network Open.

More than 70% of the overall U.S. population is estimated to have subclinical cardiovascular-kidney-metabolic syndrome, according to a research letter published in the Journal of the American College of Cardiology.

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label portion of the GRACE phase 3 trial.

ATLANTA — A remote, team-based approach with immediate initiation of necessary medications improved guideline-directed medical therapy use at 6 months for patients with diabetes at high CV or renal risk, researchers reported.

A set of newly identified genetic risk factors tied to the development of type 2 diabetes could eventually lead to the discovery of genotypes that allow providers to identify people at highest risk for complications.

ATLANTA — New results from the TACTiC trial show the promise of technology to help individuals appropriately determine if they qualify for statin therapy without a prescription.

ATLANTA — In the TACT2 trial, chelation therapy reduced levels of lead in the blood but did not improve cardiovascular outcomes for adults with diabetes and a prior heart attack.

ATLANTA — Adults with obesity, HF with preserved ejection fraction and type 2 diabetes saw marked improvements in HF symptoms and physical function with semaglutide 2.4 mg compared with placebo, despite less than typical weight loss.

ATLANTA — Monthly administration of subcutaneous olezarsen substantially reduced triglyceride levels compared with placebo among patients with predominantly moderate hypertriglyceridemia and elevated CV risk, according to new phase 2 data.